Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial
about
Glucagon-like peptide analogues for type 2 diabetes mellitusRegulation of glucose homeostasis by GLP-1Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studiesCardiovascular Effects of Glucagon-Like Peptide-1 Receptor AgonistsGlucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: Past, present, and futureEmerging utility of once-weekly exenatide in patients with type 2 diabetesIncretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitorsExenatide once-weekly injection for the treatment of type 2 diabetes in Chinese patients: current perspectivesA clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyondIncretin based therapies: a novel treatment approach for non-alcoholic fatty liver diseaseAssessment of pancreatic β-cell function: review of methods and clinical applicationsGLP-1 receptor activated insulin secretion from pancreatic β-cells: mechanism and glucose dependenceGLP-1, the gut-brain, and brain-periphery axesUpdate on the treatment of type 2 diabetes mellitusTreatment intensification in patients with inadequate glycemic control on basal insulin: rationale and clinical evidence for the use of short-acting and other glucagon-like peptide-1 receptor agonistsEfficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitusThe short-term cost-effectiveness of once-daily liraglutide versus once-weekly exenatide for the treatment of type 2 diabetes mellitus in the United StatesPharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.Exenatide once weekly: opportunities in the primary care setting.Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists Utilizing Data from the Exenatide Clinical Trial Development Program.Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program.Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus.Retrospective analysis of safety and efficacy of insulin-to-liraglutide switch in Japanese type 2 diabetes: A caution against inappropriate use in patients with reduced β-cell function.Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysisEffects of exenatide in a morbidly obese patient with type 2 diabetesAn overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes.Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION-NEO-2 randomized clinical study.Relationship of baseline HbA1c, HbA1c change and HbA1c target of < 7% with insulin analogues in type 2 diabetes: a meta-analysis of randomised controlled trials.Diabetes and cardiovascular disease: focus on glucagon-like peptide-1 based therapiesEffects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.Changes in mipomersen dosing regimen provide similar exposure with improved tolerability in randomized placebo-controlled study of healthy volunteersA local glucagon-like peptide 1 (GLP-1) system in human pancreatic islets.GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other?Selective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetesDURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide.A real world comparison of sulfonylurea and insulin vs. incretin-based treatments in patients not controlled on prior metformin monotherapy.Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes.Glucagon-like peptide 1 receptor agonist therapy is more efficacious than insulin glargine for poorly controlled type 2 diabetes: A systematic review and meta-analysis.Emerging role of insulin with incretin therapies for management of type 2 diabetes.
P2860
Q24235918-A461610D-0260-42A3-92B3-67FE1B616C12Q24563430-8950CB14-D4CC-4B5B-843C-F77874DB6FC4Q24568148-DFAF9DD7-AD49-414A-95F6-D9C3A7746541Q26749495-FBCE18CC-30EE-47B0-B29C-BCA9D7A0F36DQ26752699-76EEFF14-0AF6-4231-8BB9-2B584F40B890Q26777320-85F1297A-CF1C-404F-91B6-C9AC5FD40B1EQ26778608-88EFE7D9-748D-4D11-832F-3E7FC99F475EQ26797236-685DAD24-9557-4FB3-8DDB-98F3A73AC4B0Q26799389-5E25C2A8-09C6-4A92-BF7D-1A7D604647F8Q26827183-57AA196C-18CB-4643-8020-CE6C090BAF27Q26829445-DD6CC62D-84D5-4264-9D19-662E414C4B7CQ26858990-1BD24EEA-15AC-43DE-8010-000C0BEC43BEQ27000749-099EC1AF-1A42-44E0-AA55-9771F6694917Q28073342-B61D25DE-072F-44BE-A51B-2FF2CD0EE43EQ28077026-C569B753-2820-4EBA-BB3D-5822B9A36C3BQ28088578-0D86B6EA-E884-4807-9715-5631CF2CB820Q28545766-995579AA-D212-45B6-BEB5-4DB6C9185501Q30249371-8F474D77-7824-40F2-AE8D-071630EC7F98Q30431639-6C21A57F-46C4-43FC-B79F-1E02609D85E4Q31066859-84042F6A-C8C7-4656-AF69-E7333FF7FCA3Q31082841-286002E2-913A-4BCA-9486-C06A7C9F0264Q33603466-F2FB5F06-1A05-4144-B1D9-4829431AB714Q33607749-187BFB79-A55B-4240-A7F1-5BEDBC85A895Q33767049-52375AF6-3391-4C5F-8248-798373367097Q33785151-62594167-06C9-46DB-BBCC-0CA028E6E0C5Q33786150-9A300EF3-E171-42F6-9593-F972D2842C16Q33824522-89D66222-5BFA-44F1-8E33-E7193D824965Q33835897-FDB52437-F802-445C-AD0B-EAB17B821293Q33871459-4AF6CFFA-F065-4012-8BA3-56BC2080AFB6Q33949425-42970B5D-BB97-4F0A-828C-AD2B1AF3EA7BQ34124353-2742AA6A-87E4-466C-952F-ACB65D1C9AFFQ34297049-A7DBB8E5-470D-4C98-8D35-FB6811F5C0BAQ34410733-BB577922-1202-42A3-83F3-0CE2E823EAD8Q34547492-07DD33B5-F900-412C-9D3C-AEB2FF3F38EDQ34994502-31675A72-64D6-4D3E-B0F2-DB3881F7278AQ35069686-69DCD7D7-1A1D-45D3-9010-C89366ED5D4BQ35073584-392C7E16-6D36-4C57-9995-250E610FDA7BQ35074194-B6BD306E-AAF5-4860-8241-899C09EBD56EQ35210164-3C50A7E0-8C40-4A34-8453-123ADBB6388BQ35214425-8ED19F0E-D9B1-4CB6-9DA5-782DB6262BF3
P2860
Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Once weekly exenatide compared ...... an open-label randomised trial
@ast
Once weekly exenatide compared ...... an open-label randomised trial
@en
Once weekly exenatide compared ...... an open-label randomised trial
@nl
type
label
Once weekly exenatide compared ...... an open-label randomised trial
@ast
Once weekly exenatide compared ...... an open-label randomised trial
@en
Once weekly exenatide compared ...... an open-label randomised trial
@nl
prefLabel
Once weekly exenatide compared ...... an open-label randomised trial
@ast
Once weekly exenatide compared ...... an open-label randomised trial
@en
Once weekly exenatide compared ...... an open-label randomised trial
@nl
P2093
P921
P3181
P1433
P1476
Once weekly exenatide compared ...... an open-label randomised trial
@en
P2093
Dachuang Cao
Justin Northrup
Kristin Taylor
Luc Van Gaal
Michael Trautmann
Michaela Diamant
Stephen Stranks
P304
P3181
P356
10.1016/S0140-6736(10)60406-0
P407
P577
2010-06-26T00:00:00Z